Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Thyroxine × Head & Neck × Clear all

Phase

Phase NA 3 Phase 2 3 Phase 3 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Postoperative Complications 1 Neoplasms 1 Hypothyroidism 1

Interventions

Cisplatin 15 Radiotherapy 7 Fluorouracil 7 pembrolizumab 6 Radiotherapy, Intensity-Modulated 6 Docetaxel 6 Magnetic Resonance Spectroscopy 5 Gemcitabine 5 Platinum 4 Paclitaxel 4 1,2-diaminocyclohexaneplatinum II citrate 4 Radiation 3 Cetuximab 3 Carboplatin 3 (225)Ac-DOTA-c(RGDyK) 3 atezolizumab 2 Specimen Handling 2 Iodine-123 2 Immunoglobulin G 2 Drug Therapy 2 Disulfides 2 trametinib 1 toripalimab 1 ponatinib 1 pertuzumab 1 fosbretabulin 1 fluorocholine 1 durvalumab 1 dehydroftorafur 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02548715 2022-07-13

LSHT

University of Alberta

Phase 2/3 Withdrawn

Hypothyroidism, Neoplasms, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡